{"id":"F2025L00153","name":"Statement of Principles concerning malignant neoplasm of the endometrium (Reasonable Hypothesis) (No. 31 of 2025)","slug":"statement-of-principles-concerning-malignant-neoplasm-of-the-endometrium-reasonable-hypothesis-no-31","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":442740,"registerId":"F2025L00153-fast-fetch-1775957688178","compilationNumber":null,"startDate":"2026-04-12","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Statement of Principles concerning malignant neoplasm of the endometrium (Reasonable Hypothesis) (No. 31 of 2025)","content":"---\nmeta-content-style-type: text/css\nmeta-content-type: application/xhtml+xml; charset=utf-8\n---\n\n?xml version=\"1.0\" encoding=\"utf-8\" standalone=\"no\"?>\n\n![RMA Australian Government Coat of Arms](image.001.jpeg)\n\n \n\nStatement of Principles\n\nconcerning\n\nMALIGNANT NEOPLASM OF THE ENDOMETRIUM  (Reasonable Hypothesis)\n\n(No. 31 of 2025)\n\nThe Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(2) of the Veterans' Entitlements Act 1986.\n\n \n\nDated    18 February 2025.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nProfessor Terence Campbell AM\n\nChairperson\n\nby and on behalf of\n\nThe Repatriation Medical Authority\n\n \n\n \n\n   \n\n\nContents\n\n1 Name\n\n2 Commencement\n\n3 Authority\n\n4 Repeal\n\n5 Application\n\n6 Definitions\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n8 Basis for determining the factors\n\n9 Factors that must exist\n\n10 Relationship to service\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nSchedule 1 - Dictionary\n\n1 Definitions\n\n \n\n \n\n\n\n\n1.                Name\n\n\nThis is the Statement of Principles concerning malignant neoplasm of the endometrium (Reasonable Hypothesis) (No. 31 of 2025).\n\n1.                Commencement\n\n\n              This instrument commences on 25 March 2025.\n\n1.                Authority\n\n\nThis instrument is made under subsection 196B(2) and (8)of the Veterans' Entitlements Act 1986.\n\n1.                Repeal\n\n\nThe Statement of Principles concerning malignant neoplasm of the endometrium No. 11 of 2016 (Federal Register of Legislation No. F2016L00243) made under subsections 196B(2) and (8) of the VEA is repealed.\n\n1.                Application\n\n\nThis instrument applies to a claim to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies.\n\n1.                Definitions\n\n\nThe terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.\n\n1.                Kind of injury, disease or death to which this Statement of Principles relates\n  1.           This Statement of Principles is about malignant neoplasm of the endometrium and death from malignant neoplasm of the endometrium.\n\n\nMeaning of malignant neoplasm of the endometrium\n\n1.           For the purposes of this Statement of Principles, malignant neoplasm of the endometrium:\n  1.           means a primary malignant neoplasm arising from the cells of the mucous membrane that line the uterine cavity; and\n  2.           includes;\n    1.             carcinoma in situ and\n    2.          carcinosarcoma (also known as malignant mesodermal mixed tumour); and\n  3.           excludes;\n    1.             malignant neoplasm of the cervix;\n    2.          carcinoid tumour;\n    3.        soft tissue sarcoma of the uterus;\n    4.         non-Hodgkin's lymphoma; and\n    5.           Hodgkin's lymphoma.\n2.           While malignant neoplasm of the endometrium attracts ICD‑10‑AM code C54.1, in applying this Statement of Principles the meaning of malignant neoplasm of the endometrium is that given in subsection (2).\n3.           For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.\n\n\nDeath from malignant neoplasm of the endometrium\n\n1.           For the purposes of this Statement of Principles, malignant neoplasm of the endometrium, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's malignant neoplasm of the endometrium.\n\n\nNote: terminal event is defined in the Schedule 1 – Dictionary.\n\n1.                Basis for determining the factors\n\n\nThe Repatriation Medical Authority is of the view that there is sound medical-scientific evidence that indicates that malignant neoplasm of the endometrium and death from malignant neoplasm of the endometrium can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA.\n\nNote: MRCA, relevant service and VEA are defined in the Schedule 1 – Dictionary.\n\n1.                Factors that must exist\n\n\nAt least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting malignant neoplasm of the endometrium or death from malignant neoplasm of the endometrium with the circumstances of a person's relevant service:\n\n1.           for females aged over 35 years only, having never been pregnant for more than 8 weeks, at the time of clinical onset;\n2.           using oestrogen-only hormone replacement therapy for at least 3 months before clinical onset, and where the use of oestrogen-only hormone replacement therapy has ceased, clinical onset has occurred within 20 years of cessation;\n\n\nNote: oestrogen-only hormone replacement therapy is defined in the Schedule 1 - Dictionary.\n\n1.           having cyclical combined hormone replacement therapy where oestrogen is combined with cyclical administration of progesterone for less than 15 days during each treatment cycle, for a continuous period of at least 5 years before clinical onset. Where the use of cyclical combined hormone replacement therapy has ceased, clinical onset has occurred within 10 years of cessation;\n2.           for post-menopausal females only, undergoing treatment with tamoxifen for at least 3 months before clinical onset, and where treatment has ceased, clinical onset has occurred within 20 years of cessation.\n3.           being overweight or obese for at least 5 years within the 20 years before clinical onset;\n\n\nNote: being overweight or obese is defined in the Schedule 1 - Dictionary.\n\n1.           having diabetes mellitus for at least 5 years before clinical onset;\n2.           inability to undertake any physical activity greater than 3 METs for at least 10 years within the 30 years before clinical onset;\n\n\nNote: MET is defined in the Schedule 1 - Dictionary.\n\n1.           Having undergone treatment with Tibolone for at least 3 months before clinical onset, and where treatment has ceased, clinical onset has occurred within 10 years of cessation.\n2.           inability to obtain appropriate clinical management for malignant neoplasm of the endometrium before clinical worsening.\n\n\n1.            Relationship to service\n  1.           The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.\n  2.           The factor set out in subsection 9(9) applies only to material contribution to, or aggravation of, malignant neoplasm of the endometrium where the person's malignant neoplasm of the endometrium was suffered or contracted before or during (but did not arise out of) the person's relevant service.\n2.            Factors referring to an injury or disease covered by another Statement of Principles\n\n\nIn this Statement of Principles:\n\n1.           if a factor referred to in section 9 applies in relation to a person; and\n2.           that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(2) of the VEA;\n\n\nthen the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.\n\n \n\n \n\nSchedule 1 - Dictionary  \n\nNote:               See Section 6\n\n1               Definitions\n\nIn this instrument:\n\n                                being overweight or obese means having a Body Mass Index (BMI) of 25 or\n\n                               greater.\n\nNote; BMI is defined in the Schedule 1 – Dictionary.\n\n                               BMI means W/H2\n\n                               where:\n\n                               W is the person's weight in kilograms; and\n\n                               H is the person's height in metres.\n\n                               malignant neoplasm of the endometrium—see subsection 7(2).\n\n                               MET means a unit of measurement of the level of physical exertion.  1 MET = 3.5 ml of oxygen/kg of body weight per minute, 1.0 kcal/kg of body weight per hour or resting metabolic rate.\n\n                               MRCA means the Military Rehabilitation and Compensation Act 2004.\n\n                               oestrogen-only hormone replacement therapy means the continuous, cyclical or intermittent administration of unopposed oestrogen, including diethylstilbestrol, to combat surgically induced or naturally occurring menopause.\n\n                               relevant service means:\n\n(a)          operational service under the VEA;\n\n(b)          peacekeeping service under the VEA;\n\n(c)          hazardous service under the VEA;\n\n(d)          British nuclear test defence service under the VEA;\n\n(e)          warlike service under the MRCA; or\n\n(f)           non-warlike service under the MRCA.\n\nNote: MRCA and VEA are defined in the Schedule 1 - Dictionary.\n\n                               terminal event means the proximate or ultimate cause of death and includes the following:\n\n(a)           pneumonia;\n\n(b)           respiratory failure;\n\n(c)           cardiac arrest;\n\n(d)           circulatory failure; or\n\n(e)           cessation of brain function.\n\n                               VEA means the Veterans' Entitlements Act 1986.\n\n \n\n \n","sortOrder":0}],"analysis":{"kimi_summary":{"content_quality":"ok","complexity_score":4,"scope_assessment":{"changed":false,"description":"This is a standard replacement of an existing Statement of Principles (No. 11 of 2016). It maintains the same scope — determining compensation eligibility for endometrial cancer under veterans' legislation — and follows the established template for such instruments. The factors listed are consistent with the original purpose of linking specific medical conditions to military service through sound medical-scientific evidence."},"complexity_factors":["Multiple nested conditions with time limits (e.g., 'for at least 3 months before clinical onset, and where the use... has ceased, clinical onset has occurred within 20 years of cessation')","Demographic restrictions on specific factors (e.g., 'for females aged over 35 years only', 'for post-menopausal females only')","Cross-references to other legislation (VEA and MRCA) and other Statements of Principles","Technical medical definitions requiring specialised knowledge (ICD-10-AM codes, METs, specific drug names like Tibolone and Tamoxifen)","Mathematical formula for BMI with variable definitions","Distinction between clinical onset and clinical worsening with different rules applying to each","Exclusionary definitions (5 specific exclusions from the definition of the disease)"],"plain_english_summary":"This instrument sets the medical test for when endometrial (uterine) cancer in female veterans or current/former defence members can be linked to service for compensation under the VEA and MRCA. It specifies medical risk factors and timelines that, if present, create a \"reasonable hypothesis\" of service connection (a lower, more generous threshold than strict causation).\n\nIt replaces the 2016 guidance and determines eligibility for pensions, treatment and other veteran benefits."},"flash_summary":{"complexity_score":4,"scope_assessment":{"changed":true,"description":"This instrument repeals the earlier Statement of Principles No. 11 of 2016 (section 4) and reissues the medical criteria and definitions that govern how the Repatriation Medical Authority forms a reasonable hypothesis linking endometrial cancer to relevant service. It preserves application to claims under section 120A of the VEA and section 338 of the MRCA (section 5) while updating the enumerated factors, timing limits and technical definitions in section 9 and Schedule 1."},"complexity_factors":["Technical medical criteria and temporal windows for multiple hormone treatments and exposures (see section 9, e.g. subsections 9(1)–9(7))","Cross-references to other statutes and Statements of Principles (application under s120A VEA and s338 MRCA; interaction rule in section 11)","Precise defined terms and numeric thresholds (BMI ≥25, MET definition, durations and cessation windows) in Schedule 1","Requirement that listed factors be ‘related to the relevant service’, creating a legal causation layer on top of medical findings (section 10)","Repeal and replacement of an earlier instrument (section 4), requiring attention to transitional or precedent claims"],"plain_english_summary":"This instrument (commencing 25 March 2025) replaces the 2016 Statement and declares the Repatriation Medical Authority’s medical criteria for when malignant neoplasm of the endometrium can be reasonably linked to a person’s relevant service. It lists specified medical risk factors, timing windows and definitions (e.g. BMI, MET, hormone therapies) that, if present and shown to be related to service, form the basis for a reasonable hypothesis in claims under section 120A of the VEA or section 338 of the MRCA."},"flash_summary_failed":{"failed":true,"reason":"A positive credit balance is required for all requests, including BYOK, so fallback providers remain available. Add credits at https://vercel.com/d?to=%2F%5Bteam%5D%2F%7E%2Fai%3Fmodal%3Dtop-up to continue.","source":"analysis-cron"}},"importantCases":[],"_links":{"self":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-endometrium-reasonable-hypothesis-no-31","history":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-endometrium-reasonable-hypothesis-no-31/history","analysis":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-endometrium-reasonable-hypothesis-no-31/analysis","conflicts":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-endometrium-reasonable-hypothesis-no-31/conflicts","importantCases":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-endometrium-reasonable-hypothesis-no-31/important-cases","documents":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-endometrium-reasonable-hypothesis-no-31/documents"}}